Hydrophobic fractionation enhances novel protein detection by mass spectrometry in triple negative breast cancer

Journal of Proteomics and Bioinformatics

Volumn 3, Issue 2, 2010, Pages 29-38

  Lu, Ming ^a   Whitelegge, Julian P ^b   Whelan, Stephen A ^a   He, Jianbo ^a   Saxton, Romaine E ^a   Faull, Kym F ^b   Chang, Helena R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer biomarker; Hydrophobic fractionation; Mass spectrometry; Triple negative breast cancer

Indexed keywords

EID: 77149125260     PISSN: None     EISSN: 0974276X     Source Type: Journal    
DOI: 10.4172/jpb.1000118     Document Type: Article

References (47)

1. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)- negative, and HER2-negative invasive breast cancer, the so-called triplenegative phenotype: a populationbased study from the California cancer Registry. Cancer 109: 1721-1728.
2. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama 295: 2492-2502.
3. Charpidou A, Blatza D, Anagnostou E, Syrigos KN (2008) EGFR mutations in non-small cell lung cancer-clinical implications. In Vivo 22: 529-536.
4. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8: 235-244.
5. Craig R, Beavis RC (2003) A method for reducing the time required to match protein sequences with tandem mass spectra. Rapid Commun Mass Spectrom 17: 2310-2316.
6. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, et al. (2008) High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. [Epub ahead of print].
7. Diaz LK, Cryns VL, Symmans WF, Sneige N (2007) Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 14: 419-430.
8. Ginestier C, Korkaya H, Dontu G, Birnbaum D, Wicha MS, et al. (2007) The cancer stem cell: the breast cancer driver. Med Sci 23: 1133-1139.
9. Günthert U, Hofmann M, Reber R, Rudy W, Reber S, et al. (1991) A new variant of glycoprotein CD44 confers metabolic potential to rat carcinoma cells. Cell 65: 13-24.
10. Günthert U (1993) CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 184: 47-63.
11. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, et al. (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13: 1198-1207.
12. He J, Gornbein J, Shen D, Lu M, Rovai LE, et al. (2007) Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry. Int J Oncol 30: 145-154.
13. He J, Shen D, Chung DU, Saxton RE, Whitelegge JP, et al. (2009) Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy. Int J Oncol 35: 683-692.
14. Hirokawa T, Boon-Chieng S, Mitaku S (1998) SOSUI: classification and secondary structure prediction system for membrane proteins. Bioinformatics14: 378-379.
15. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1: 727-730.
16. Imai K, Ichibangase T, Saitoh R, Hoshikawa Y (2008) A proteomics study on human breast cancer cell lines by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry. Biomed Chromatogr 22: 1304-1314.
17. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
18. Kang SP, Martel M, Harris LN (2008) Triple negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol 20: 40-46.
19. Keller A, Nesvizhskii AI, Kolker E, Aebersold R (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/ MS and database search. Anal Chem 74: 5383-5392.
20. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) The international human genome sequencing consortium: initial sequencing and analysis of the human genome. Nature 409: 860-921.
21. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Clin Oncol100: 672-679.
22. Liu S, Sun MZ, Tang JW, Wang Z, Sun C, et al. (2008) High-performance liquid chromatography/nanoelectrospray ionization tandem mass spectrometry, two-dimensional difference in-gel electrophoresis and gene microarray identification of lymphatic metastasis-associated biomarkers. Rapid Commun Mass Spectrom 22: 3172-3178.
23. Liu Y, Xiao Z, Li M, Chen YH, Li C, et al. (2009) Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol 106:570-579.
24. Mercurio AM, Rabinovitz I (2001) Towards a mechanistic understanding of tumor invasion - lessons from the α6 β4 integrin. Semin Cancer Biol 11: 129-141.
25. Mohammed RA, Green A, El-Shikh S, Paish EC, Ellis IO, Martin SG (2007) Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer 96: 1092-1100.
26. Nesvizhskii AI, Keller A, Kolker E, Aebersold R (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75: 4646-4658.
27. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374.
28. Nikolopoulous SN, Blaikie P, Yoshioka T, Guo W, Giancotti FG (2004) Integrin β4 signaling promotes tumor angiogenesis. Cancer Cell 6: 471-483.
29. Relf M, LeJeune S, Scott PA, Fox S, Smith K, et al. (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57: 963-969.
30. Rubinstein DB, Karmely M, Pichinuk E, Ziv R, Benhar I, et al. (2009) The MUC1 oncoprotein as a functional target: immunotoxin binding to alpha/ beta junction mediates cell killing. Int J Cancer 124: 46-54.
31. Russ AP, Lampel S (2005) The druggable genome: An update. Drug Discov Today 10: 1607-1610.
32. Shau H, Chandler GS, Whitelegge JP, Gornbein JA, Faull KF, et al. (2003) Proteomic profiling of cancer biomarkers. Brief Funct Genomic Proteomic 2: 147-158.
33. Shen D, Chang HR, Chen Z, He J, Lonsberry V, et al. (2005) Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses. Biochem Biophys Res Commun 326: 218-227.
34. Shen D, Nooraie F, Elshimali Y, Lonsberry V, He J, et al. (2006) Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. Hum Pathol 37: 1583-1591.
35. Soo ET, Yip GW, Lwin ZM, Kumar SD, Bay BH (2008) Heat shock proteins as novel therapeutic targets in cancer. In Vivo 22: 311-315.
36. Speers AE, Wu CC (2007) Proteomics of integral membrane proteins - theory and application. Chem Rev 107: 3687-3714.
37. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, et al. (2001) The sequence of the human genome. Science 291: 1304-1351.
38. Wang GY, Lu CQ, Zhang RM, Hu XH, Luo ZW (2008) The E-cadherin gene polymorphism 160C->A and cancer risk: A HuGE review and meta-analysis of 26 case-control studies. Am J Epidemiol 167: 7-14.
39. Whelan SA, Lu M, He J, Yan W, Saxton RE, et al. (2009) Mass spectrometry (LCMS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers. J Proteome Res 8: 4151-4160.
40. White-Gilbertson S, Rubinchik S, Voelkel-Johnson C (2008) Transformation, translation and TRAIL: an unexpected intersection. Cytokine Growth Factor Rev 19: 167-172.
41. Whitelegge JP, Gunderson CB, Faulk KF (1998) Electrospray-ionization mass spectrometry of intact intrinsic membrane proteins. Protein Sci 7: 1423-1430.
42. Whitelegge JP, Halgand F, Souda P, Zabrouskov V (2006) Top-down mass spectrometry of integral membrane proteins. Expert Rev Proteomics 3: 585-596.
43. Whitelegge JP, Katz J, Pihakari K, Hale R, Aguilera R, et al. (2004) Subtle modification of isotope ratio proteomics (SMIRP); a new strategy for expression proteomics. Phytochemistry 65: 1507-1515.
44. Whitelegge JP, Le Coutre J, Lee JC, Engel CK, Privé GG, et al. (1999) Towards the bilayer proteome electrospray ionization mass spectrometry of large intact membrane proteins. Proc Natl Acad Sci 96: 10695-10698.
45. Whitelegge JP (2005a) Mass spectrometry for high throughput quantitative proteomics in plant research: lessons from thylakoid membranes. Plant Physiol Biochem 42: 919-927.
46. Whitelegge JP (2005b) Tandem Mass Spectrometry of Integral Membrane Proteins for Top-Down Proteomics. Trends Anal Chem 24: 576-582.
47. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, et al. (1993) Expression of GD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53: 4754-4756.